
WHAT IS CLAIMED:

1. A compound of Formula I:




(I)

Wherein

A is absent, -(C=O)-, -S(O)$_2$-, -C(=N-OR$_1$)- or -C(=N-CN)-;

B is selected from -C$_3$-C$_{12}$ cycloalkyl, substituted -C$_3$-C$_{12}$ cycloalkyl; -C$_3$-C$_{12}$ cycloalkenyl, substituted -C$_3$-C$_{12}$ cycloalkenyl; -C$_3$-C$_{12}$ heterocycloalkyl, and substituted -C$_3$-C$_{12}$ heterocycloalkyl;

or B is , wherein R$_7$ and R$_8$ are each independently C$_1$-C$_8$ alkyl or C$_2$-C$_8$ alkenyl and are each independently optionally substituted with one or more halo;

M$_1$ and M$_2$ are each independently selected from O or NR$_1$;

each R$_1$ is independently selected at each occurrence from the group consisting of:

(i) hydrogen;

(ii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(iii) heterocycloalkyl or substituted heterocycloalkyl; and

(iv) C$_1$-C$_8$ alkyl, C$_2$-C$_8$ alkenyl, or C$_2$-C$_8$ alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted -C$_1$-C$_8$ alkyl, substituted -C$_2$-C$_8$ alkenyl, or substituted -C$_2$-C$_8$ alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; -C$_3$-C$_{12}$ cycloalkyl, substituted -C$_3$-C$_{12}$ cycloalkyl; -C$_3$-C$_{12}$ cycloalkenyl, or substituted -C$_3$-C$_{12}$ cycloalkenyl;

L$_1$ and L$_2$ are each independently selected from -C$_1$-C$_8$ alkylene, -C$_2$-C$_8$ alkenylene, or -C$_2$-C$_8$ alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or

~~N; substituted –C_1-C_8 alkylene, substituted –C_2-C_8 alkenylene, or substituted –C_2-C_8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkylene, or substituted –C_3-C_{12} cycloalkylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkenylene, and substituted –C_3-C_{12} cycloalkenylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;~~

~~W is absent, –O–, –S–, –NH–, –N(Me)–, –C(O)NH–, or –C(O)N(Me)–;~~

~~X and Y taken together with the carbon atoms to which they are attached to form a cyclic moiety which selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocylic, carbocyclic, and substituted carbocyclic;~~

~~X' is N or –C(R_2)–, where R_2 is selected from the group consisting of:~~

~~(i) hydrogen, halogen, CN, CF_3, NO_2, OR_3, SR_3, –$NHS(O)_2$–R_3, –$NH(SO_2)NR_4R_5$, NR_4R_5, CO_2R_3, COR_3, $CONR_4R_5$, $N(R_1)COR_3$; aryl; substituted aryl; heteroaryl; or substituted heteroaryl;~~

~~(ii) heterocycloalkyl or substituted heterocycloalkyl; and~~

~~(iii) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl;~~

~~each R_3 is independently selected from C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; and –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl; heterocylic; substituted heterocylic; aryl; substituted aryl; heteroaryl; or substituted heteroaryl;~~

~~each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;~~

R and R' are each independently selected from the group consisting of:

(i) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, r substituted C_3-C_{12} cycloalkyl; C_4-C_{12} alkylcycloalkyl, substituted C_4-C_{12} alkylcycloalkyl; C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; C_4-C_{12} alkylcycloalkenyl, or substituted C_4-C_{12} alkylcycloalkenyl;

(ii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;


(iii) heterocycloalkyl or substituted heterocycloalkyl; and

(iv) hydrogenor deuterium;

G is selected from OH, $NHS(O)_2$ R_3, $-NH(SO_2)NR_4R_5$, and NR_4R_5; and

R" is selected from hydrogen, methyl, ethyl, and allyl.

2. The compound of claim 1, wherein the compound is of Formula II:



(II)

or a pharmaceutically acceptable salt, ester or prodrug thereof, alone or in combination with a pharmaceutically acceptable carrier or excipient, where X_1-X_4 are independently selected from CR_6 and N, wherein each R_6 is independently selected from:

(i) hydrogen; halogen; $-NO_2$; -CN; or N_3;

(ii) M-R_3, wherein M is O, S, NH;

(iii) NR_4R_5;

(iv) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing


0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;

(v) aryl; substituted aryl; heteroaryl; or substituted heteroaryl; and

(vi) heterocycloalkyl or substituted heterocycloalkyl;

A is absent, $-(C=O)-$, $-S(O)_2-$, $-C(=N-OR_1)-$ or $-C(=N-CN)-$;

B is selected from C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; C_3-C_{12} heterocycloalkyl, and substituted C_3-C_{12} heterocycloalkyl;

or B is 

, wherein R_7 and R_8 are each independently C_1-C_8 alkyl or C_2-C_8 alkenyl and are each independently optionally substituted with one or more halo;

M_1 and M_2 are each independently selected from O and NR_1;

each R_1 is independently selected at each occurrence from the group consisting of:

(i) hydrogen;

(ii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(iii) heterocycloalkyl or substituted heterocycloalkyl; and

(iv) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;

L_1 and L_2 are each independently selected from C_1-C_8 alkylene, C_2-C_8 alkenylene, or C_2-C_8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkylene, substituted C_2-C_8 alkenylene, or substituted C_2-C_8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkylene, or substituted C_3-C_{12} cycloalkylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkenylene or substituted C_3-C_{12} cycloalkenylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;

W is absent, –O–, –S–, –NH–, –N(Me)–, –C(O)NH–, or –C(O)N(Me)–;

X' is N or –C(R_2)–, where R_2 is selected from the group consisting of:

(i) hydrogen, halogen, CN, CF_3, NO_2, OR_3, SR_3, –$NHS(O)_2$–R_3, –$NH(SO_2)NR_4R_5$, NR_4R_5, CO_2R_3, COR_3, $CONR_4R_5$, $N(R_1)COR_3$; aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(ii) heterocycloalkyl or substituted heterocycloalkyl; and

(iii) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, or substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl;

each R_3 is independently selected from C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; heterocylic; substituted heterocyclic; aryl; substituted aryl; heteroaryl; and substituted heteroaryl;

each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;

R and R' are each independently selected from the group consisting of:

(i) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_4-C_{12} alkylcycloalkyl, substituted –C_4-C_{12} alkylcycloalkyl; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; –C_4-C_{12} alkylcycloalkenyl, or substituted –C_4-C_{12} alkylcycloalkenyl;

(ii) aryl; substituted aryl; heteroaryl; substituted heteroaryl;


(iii) heterocycloalkyl or substituted heterocycloalkyl; and

(iv) hydrogen; deuterium;

~~G is selected from –OH, –NHS(O)$_2$–R$_3$, –NH(SO$_2$)NR$_4$R$_5$, and NR$_4$R$_5$; and~~

~~R" is selected from hydrogen, methyl, ethyl, and allyl.~~

~~3. The compound of claim 1, wherein the compound is of Formula III or IV:~~



(III) (IV)

~~or a pharmaceutically acceptable salt, ester or prodrug thereof, alone or in combination with a pharmaceutically acceptable carrier or excipient, where each Y$_1$ and Y$_2$ are independently selected from CR$_6$, N, and each Y$_3$ is selected from NR$_6$, S and O;~~

~~each R$_6$ is independently selected from:~~

~~(i) hydrogen; halogen; –NO$_2$; –CN; or N$_3$;~~

~~(ii) –M-R$_3$, wherein M is O, S, or NH;~~

~~(iii) NR$_4$R$_5$;~~


~~(iv) –C$_1$-C$_8$ alkyl, –C$_2$-C$_8$ alkenyl, or –C$_2$-C$_8$ alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C$_1$-C$_8$ alkyl, substituted –C$_2$-C$_8$ alkenyl, or substituted –C$_2$-C$_8$ alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C$_3$-C$_{12}$ cycloalkyl, substituted –C$_3$-C$_{12}$ cycloalkyl; –C$_3$-C$_{12}$ cycloalkenyl, or substituted –C$_3$-C$_{12}$ cycloalkenyl;~~

~~(v) aryl; substituted aryl; heteroaryl; or substituted heteroaryl; and~~

~~(vi) heterocycloalkyl or substituted heterocycloalkyl;~~

~~A is absent, –(C=O)–, –S(O)$_2$–, –C(=N-OR$_1$)– or –C(=N-CN)–;~~

~~Ⓑ is selected from –C$_3$-C$_{12}$ cycloalkyl, substituted –C$_3$-C$_{12}$ cycloalkyl; –C$_3$-C$_{12}$ cycloalkenyl, substituted –C$_3$-C$_{12}$ cycloalkenyl; –C$_3$-C$_{12}$ heterocycloalkyl, and substituted –C$_3$-C$_{12}$ heterocycloalkyl;~~

or B is 

, wherein R_7 and R_8 are each independently C_1-C_8 alkyl or C_2-C_8 alkenyl and are each independently optionally substituted with one or more halo;

M_1 and M_2 are each independently selected from O and NR_1;

each R_1 is independently selected at each occurrence from the group consisting of:

(v) hydrogen;

(vi) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(vii) heterocycloalkyl or substituted heterocycloalkyl; and

(viii) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;

L_1 and L_2 are each independently selected from C_1-C_8 alkylene, C_2-C_8 alkenylene, or C_2-C_8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkylene, substituted C_2-C_8 alkenylene, or substituted C_2-C_8 alkynylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkylene, or substituted C_3-C_{12} cycloalkylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkenylene, or substituted C_3-C_{12} cycloalkenylene each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;

W is absent, O, S, NH, N(Me), C(O)NH, or C(O)N(Me);

X' is N or $C(R_2)$, where R_2 is selected from the group consisting of:

(iv) hydrogen, halogen, CN, CF_3, NO_2, OR_3, SR_3, $NHS(O)_2R_3$, $NH(SO_2)NR_4R_5$, NR_4R_5, CO_2R_3, COR_3, $CONR_4R_5$, $N(R_1)COR_3$; aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(v) heterocycloalkyl or substituted heterocycloalkyl; and

(vi) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3

heteroatoms selected from O, S or N; –C_3-C_{12}-cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12}-cycloalkenyl, or substituted –C_3-C_{12}-cycloalkenyl;

each R_3 is independently selected from C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12}-cycloalkyl; –C_3-C_{12}-cycloalkenyl, substituted –C_3-C_{12}-cycloalkenyl; heterocylic; substituted heterocyclic; aryl; substituted aryl; heteroaryl; and substituted heteroaryl;

each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;

R and R'are each independently selected from the group consisting of:

(v) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12}-cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_4-C_{12}-alkylcycloalkyl, substituted –C_4-C_{12}-alkylcycloalkyl; –C_3-C_{12}-cycloalkenyl, substituted –C_3-C_{12}-cycloalkenyl; –C_4-C_{12}-alkylcycloalkenyl, or substituted –C_4-C_{12}-alkylcycloalkenyl;

(vi) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;


(vii) heterocycloalkyl or substituted heterocycloalkyl; and

(viii) hydrogen or deuterium;

G is selected from –OH, –$NHS(O)_2$–R_3, –$NH(SO_2)NR_4R_5$, and NR_4R_5; and

R" is selected from hydrogen, methyl, ethyl, and allyl.

4. The compound of claim 1, wherein the compound is of Formula V:



(V)

or a pharmaceutically acceptable salt, ester or prodrug thereof, alone or in combination with a pharmaceutically acceptable carrier or excipient, wherein

X_1-X_4 are independently selected from –CR_6- and N, wherein each R_6 is independently selected from:

(vii) hydrogen; halogen; -NO_2; -CN; or N_3;

(viii) –M-R_3, where M is O, S, or NH;

(ix) NR_4R_5;


(x) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl;

(xi) aryl; substituted aryl; heteroaryl; or substituted heteroaryl; and

(xii) heterocycloalkyl or substituted heterocycloalkyl;

A is absent, –(C=O)–, –S(O)$_{2}$–, -C(=N-OR_1)- or –C(=N-CN)-;

B is selected from –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; –C_3-C_{12} heterocycloalkyl, and substituted –C_3-C_{12} heterocycloalkyl;

or B is , wherein R_7 and R_8 are each independently C_1-C_8 alkyl or C_2-C_8 alkenyl and are each independently optionally substituted with one or more halo;

M_1 and M_2 are each independently selected from O and NR_1;

each R_1 is independently selected at each occurrence from the group consisting of:

(ix) hydrogen;

(x) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(xi) heterocycloalkyl or substituted heterocycloalkyl; and

(xii) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;

X' is N or $C(R_2)$, where R_2 is selected from the group consisting of:

(vii) hydrogen, halogen, CN, CF_3, NO_2, OR_3, SR_3, $NHS(O)_2R_3$, $NH(SO_2)NR_4R_5$, NR_4R_5, CO_2R_3, COR_3, $CONR_4R_5$, $N(R_1)COR_3$; aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(viii) heterocycloalkyl or substituted heterocycloalkyl; and

(ix) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;

each R_3 is independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; heterocylic; substituted heterocyclic; aryl; substituted aryl; heteroaryl; and substituted heteroaryl;

each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;

R and R' are each independently selected from the group consisting of:

(ix) C_1-C_8 alkyl, C_2-C_8 alkenyl, or C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12}

~~cycloalkyl; C_4-C_{12} alkylcycloalkyl, substituted C_4-C_{12} alkylcycloalkyl; C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; C_4-C_{12} alkylcycloalkenyl, or substituted C_4-C_{12} alkylcycloalkenyl;~~

~~(x) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;~~


~~(xi) heterocycloalkyl or substituted heterocycloalkyl; and~~

~~(xii) hydrogen; or deuterium;~~

~~G is selected from –OH, –$NHS(O)_2$–R_3, –$NH(SO_2)NR_4R_5$, and NR_4R_5; and~~

~~R" is selected from hydrogen, methyl, ethyl, and allyl.~~

15. ~~The~~ A compound of ~~claim 1, wherein the compound is of~~ Formula VI:



(VI)

or a pharmaceutically acceptable salt~~,~~ or ester ~~or prodrug~~ thereof, alone or in combination with a pharmaceutically acceptable carrier or excipient, wherein

X_1-X_4 are ~~independently~~ selected from –CR_6 ~~and N~~, wherein each R_6 is hydrogen~~independently selected from:~~

~~(xiii) hydrogen; halogen; $-NO_2$; –CN; or N_3;~~

~~(xiv) M-R_3, wherein M is O, S, or NH;~~


~~(xv) NR_4R_5;~~

~~(xvi) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted C_1-C_8 alkyl, substituted C_2-C_8 alkenyl, or substituted C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, or substituted C_3-C_{12} cycloalkenyl;~~

~~(xvii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl; and~~

~~(xviii)~~(i) ~~heterocycloalkyl or substituted heterocycloalkyl;~~

Ⓑ is selected from –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; or ~~–C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl;~~ –C_3-C_{12} heterocycloalkyl~~, and substituted –C_3-C_{12} heterocycloalkyl~~;

~~or Ⓑ is~~ 

~~, wherein R_7 and R_8 are each independently C_1-C_8 alkyl or C_2-C_8 alkenyl and are each independently optionally substituted with one or more halo;~~

M_1 and M_2 are each independently selected from O and NR_1;

each R_1 is hydrogen;~~independently selected at each occurrence from the group consisting of:~~

~~(xiii) hydrogen;~~

~~(xiv) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;~~

~~(xv) heterocycloalkyl or substituted heterocycloalkyl; and~~

~~(xvi)~~(i) ~~–C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl;~~

each R_3 is independently selected from ~~–C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;~~ –C_3-C_{12} cycloalkyl~~,~~ or substituted –C_3-C_{12} cycloalkyl~~; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; heterocylic; substituted heterocyclic; aryl; substituted aryl; heteroaryl; and substituted heteroaryl~~;

~~each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;~~

R and R'are each independently selected from the group consisting of:

~~(xiii)~~ –C_1-C_8 alkyl, –C_2-C_8 alkenyl, ~~or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;~~ substituted –C_1-C_8 alkyl, ~~substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;~~ –C_3-C_{12} cycloalkyl, or~~substituted –C_3-C_{12} cycloalkyl; –C_4-C_{12} alkylcycloalkyl, substituted –C_4-C_{12} alkylcycloalkyl;~~

~~C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; C_4-C_{12} alkylcycloalkenyl, or substituted C_4-C_{12} alkylcycloalkenyl;~~

~~(xiv)~~(i) ~~aryl; substituted aryl; heteroaryl; or substituted heteroaryl;~~


~~(xv)~~ heterocycloalkyl ~~or substituted heterocycloalkyl; and~~

~~(xvi)~~(ii) ~~hydrogen; or deuterium~~;

G is selected from ~~–OH,~~ –NHS(O)$_2$–R_3~~, –NH(SO$_2$)NR$_4$R$_5$, and NR$_4$R$_5$~~; and

R" is selected from hydrogen~~, methyl, ethyl, and allyl~~.

2~~6~~. The compound~~s~~ of claim 1, wherein the compound is of Formula VII:




(VII)

wherein

$R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are each hydrogen~~independently R_6, or $R^{1'}$ and $R^{2'}$, $R^{2'}$ and $R^{3'}$, or $R^{3'}$ and $R^{4'}$ combined together with the carbons they are attached to form aromatic or heteroaromatic or cyclic or heterocyclic ring;~~

~~Ⓑ is selected from C_3-C_{12} cycloalkyl, substituted C_3-C_{12} cycloalkyl; C_3-C_{12} cycloalkenyl, substituted C_3-C_{12} cycloalkenyl; C_3-C_{12} heterocycloalkyl, and substituted C_3-C_{12} heterocycloalkyl;~~

~~or Ⓑ is~~  ~~, wherein R_7 and R_8 are each independently C_1-C_8 alkyl or C_2-C_8 alkenyl and are each independently optionally substituted with one or more halo;~~

~~each R_6 is independently selected from:~~

~~(xix) hydrogen; halogen; $-NO_2$; –CN; or N_3;~~

~~(xx) –M-R_3, wherein M is O, S, or NH;~~

~~(xxi) NR_4R_5;~~

(xxii) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, or substituted –C_3-C_{12} cycloalkenyl;

(xxiii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl; and

(xxiv) heterocycloalkyl or substituted heterocycloalkyl;

R_3 is independently selected from C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; heterocylic; substituted heterocyclic; aryl; substituted aryl; heteroaryl; and substituted heteroaryl;

each R_4 and R_5 are independently selected from H and R_3, or R_4 and R_5 combined together with the N they are attached to form a heterocyclic ring;

R and R'are each independently selected from the group consisting of:

(xvii) –C_1-C_8 alkyl, –C_2-C_8 alkenyl, or –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted –C_1-C_8 alkyl, substituted –C_2-C_8 alkenyl, or substituted –C_2-C_8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; –C_3-C_{12} cycloalkyl, substituted –C_3-C_{12} cycloalkyl; –C_4-C_{12} alkylcycloalkyl, substituted –C_4-C_{12} alkylcycloalkyl; –C_3-C_{12} cycloalkenyl, substituted –C_3-C_{12} cycloalkenyl; –C_4-C_{12} alkylcycloalkenyl, or substituted –C_4-C_{12} alkylcycloalkenyl;

(xviii) aryl; substituted aryl; heteroaryl; or substituted heteroaryl;

(xix) heterocycloalkyl or substituted heterocycloalkyl; and

(xx) hydrogen; or deuterium; and


R" is selected from hydrogen, methyl, ethyl, and allyl.

7. The compound of claim 6, wherein  is C_3-C_{12} cycloalkyl or 4- to 6-membered heterocycloalkyl and is optionally substituted with one or more substituents independently selected from halo, C_1-C_8 alkyl or C_2-C_8 alkenyl.

38. The compound of claim 72, wherein Ⓑ is a non-aromatic C_3-C_6 cycloalkyl or a non-aromatic 4- to 6-membered heterocycloalkyl and is optionally substituted with one or more substituents independently selected from halo, C_1-C_6 alkyl or C_2-C_6 alkenyl.


49. The compound of claim 38, wherein Ⓑ is saturated C_4-C_6 cycloalkyl or saturated 4- to 6-membered heterocycloalkyl and is optionally substituted with one or more substituents independently selected from halo, C_1-C_8 C_6 alkyl or C_2-C_8 alkenyl.


510. The compound of claim 38, wherein Ⓑ is selected from:




.


11. The compound of claim 6, wherein (a) $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are hydrogen; (b) $R^{1'}$ and $R^{4'}$ are hydrogen; and one of $R^{2'}$ and $R^{3'}$ is hydrogen, and the other is selected from halo, methyl optionally substituted with one or more halo, or -O-methyl optionally substituted with one or more halo; (c) $R^{1'}$ and $R^{2'}$, or $R^{2'}$ and $R^{3'}$, or $R^{3'}$ and $R^{4'}$, taken together with carbon atoms to which they are attached, form a 5- or 6-membered carbocycle or heterocycle (e.g., phenyl), and the rest of $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are hydrogen.


612. The compound of claim 26, wherein R_3 is  or .


713. The compound of claim 26, wherein R' is .


814. The compound of claim 26, wherein R is .


915. The compound of claim 26, wherein:

(a) B is , R' is vinyl () or difluoromethyl (), R_3 is , and R is ;

~~(b) B is , R' is vinyl () or difluoromethyl (), R_3 is , and R is , $R^{3'}$ is –O-methyl optionally substituted with one or more halo, and $R^{1'}$, $R^{2'}$, and $R^{4'}$ are hydrogen;~~

(c) B is , R' is vinyl () or difluoromethyl (), R_3 is , and R is  and $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are hydrogen.~~,~~

~~(d) B is , R' is vinyl () or difluoromethyl (), R_3 is , and R is , $R^{3'}$ is halo, and $R^{1'}$, $R^{2'}$, and $R^{4'}$ are hydrogen; or~~

~~(e) B is , R' is vinyl () or difluoromethyl (), R_3 is , and R is , $R^{3'}$ and $R^{4'}$ taken together with carbon atoms to which they are attached form phenyl, and $R^{1'}$ and $R^{2'}$ are hydrogen.~~

10~~16~~. A pharmaceutical composition comprising an inhibitory amount of a compound according to claim 1 or a pharmaceutically acceptable salt~~,~~ or ester~~, or prodrug~~ thereof, in combination with a pharmaceutically acceptable carrier or excipient.

11~~17~~. ~~A method of treating a viral infection in a subject, comprising administering to the subject an~~ An inhibitory amount of a pharmaceutical composition according to claim 10~~16~~ for use in the manufacture of a medicament for treating a viral infection in a subject.

12~~18~~. The ~~method~~ composition according to claim 11~~17~~, wherein the viral infection is hepatitis C virus.

13~~19~~. ~~A method of inhibiting the replication of hepatitis C virus, the method comprising supplying a~~ A hepatitis C viral NS3 protease inhibitory amount of the pharmaceutical

composition of claim 10~~16~~ for use in the manufacture of a medicament for inhibiting the replication of hepatitis C virus.

14~~20~~. The ~~method~~ composition of claim 11~~17~~, further comprising administering concurrently an additional anti-hepatitis C virus agent;

wherein the additional anti-hepatitis C virus agent is selected from the group consisting of α-interferon, β-interferon, ribavirin, and amantadine.

~~21. The method of claim 20, wherein said additional anti-hepatitis C virus agent is selected from the group consisting of α-interferon, β-interferon, ribavarin, and adamantine.~~

~~22. The method of claim 20, wherein said additional anti-hepatitis C virus agent is an inhibitor of hepatitis C virus helicase, polymerase, metalloprotease, or IRES.~~

15~~23~~. The pharmaceutical composition of claim 10~~16~~, further comprising another anti-HCV agent;


wherein the another anti-hepatitis C virus agent is selected from the group consisting of α-interferon, β-interferon, ribavirin, and amantadine.

~~24. The pharmaceutical composition of claim 16, further comprising an agent selected from interferon, ribavirin, amantadine, another HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor.~~


16~~25~~. The pharmaceutical composition of claim 10~~16~~, further comprising pegylated interferon.

~~26. The pharmaceutical composition of claim 16, further comprising another anti-viral, anti-bacterial, anti-fungal or anti-cancer agent, or an immune modulator.~~

























17. The compound of claim 5 according to Formula VIII wherein R, -L_2-W-L_1-,























































, R' and G are delineated for each example in the following table:























































(VIII)



























Example#	R	-L_2-W-L_1-		R'	G
1.					
2.					
3.					
4.					
5.					
6.					
7.					



























8.					
9.					
10.					
11.					
12.					
13.					
14.					
15.					
16.					
17.					
18.					
19.					



























20.					
21.					
22.					
23.					
24.					
25.					
26.					
27.					
28.					
29.					
30.					
31.					



























32.					
33.					
34.					
35.					
36.					
37.					
38.					
39.					
40.					
41.					
42.					
43.					



























44.					
45.					
46.					
47.					
48.					
49.					
50.					
51.					
52.					
53.					
54.					



























55.					
56.					
57.					
58.					
59.					
60.					
61.					
62.					
63.					
64.					
65.					
66.					



























67.					
68.					
69.					
70.					
71.					
72.					
73.					
74.					
75.					
76.					



























77.					
78.					
79.					
80.					
81.					
82.					
83.					
84.					
85.					
86.					



























87.					
88.					
89.					
90.					
91.					
92.					
93.					
94.					
95.					
96.					
97.					



























98.					
99.					
100.					
101.					
102.					
103.					
104.					
105.					
106.					
107.					
108.					



























109.					
110.					
111.					
112.					
113.					
114.					
115.					
116.					
117.					
118.					
119.					



























120.					
121.					
122.					
123.					
124.					
125.					
126.					
127.					
128.					
129.					
130.					
131.					



























132.					
133.					
134.					
135.					
136.					
137.					
138.					
139.					
140.					
141.					
142.					
143.					



























144.					
145.					
146.					
147.					
148.					
149.					
150.					
151.					
152.					
153.					
154.					
155.					



























156.					
157.					
158.					
159.					
160.					
161.					
162.					
163.					
164.					
165.					
166.					



























167.					
168.					
169.					
170.					
171.					
172.					
173.					
174.					
175.					
176.					
177.					
178.					



























179.					
180.					
181.					
182.					
183.					
184.					
185.					
186.					
187.					
188.					



























189.					
190.					
191.					
192.					
193.					
194.					
195.					
196.					
197.					
198.					

199.					
200.					
201.					
202.					
203.					
204.					
205.					
206.					
207.					
208.					
209.					


210.					
211.					
212.					
213.					
214.					
215.					
216.					
217.					
218.					
219.					
220.					

221.					
222.					
223.					
224.					
225.					
226.					
227.					
228.					
229.					
230.					
231.					
232.					

233.					
234.					
235.					
236.					
237.					
238.					
239.					
240.					
241.					
242.					
243.					
244.					

245.					
246.					
247.					
248.					
249.					
250.					
251.					
252.					
253.					
254.					
255.					
256.					


18. A compound that is:



;

or a pharmaceutically acceptable salt thereof.

19. A compound that is:



;

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising an inhibitory amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

21. A pharmaceutical composition comprising an inhibitory amount of a compound according to claim 19 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

22. An inhibitory amount of a pharmaceutical composition according to any one of claims 20 or 21 for use in the manufacture of a medicament for treating a viral infection in a subject.

23. The composition according to claim 22, wherein the viral infection is hepatitis C virus.